To be clear on OTC regulation


A US humorist once quipped: “Ancient Rome declined because it had a Senate. Now what’s going to happen to us with both a House and a Senate?” The derivatives industry will be asking the same question as the US Senate prepares to follow the House of Representatives and pass its own version of over-the-counter derivatives legislation.

The crucial questions are about scope – specifically, whether derivatives end-users and foreign exchange swaps and forwards will be exempt from requirements on

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

If you already have an account, please sign in here.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here